Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business. Read why I think HIMS stock is ...

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

Overall, Novo is expecting slower growth in 2025. The company is guiding for sales to rise between 16% and 24%, down from 26% ...

Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic ...

So toss the weight chart ... semaglutide (Wegovy or Ozempic). Metformin. Metformin is primarily used to improve blood sugar regulation in those with type 2 diabetes, but it may also support weight ...

Men, especially, were less likely to agree with medical necessity and more likely to stress the role of personal ...

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

Novo Nordisk filed for approval of an oral, 25-mg formulation of its weight loss blockbuster “earlier this year,” according ...

An estimated 24,499 people visited the ED for adverse events related to semaglutide in the 2 years after its approval for ...

Tirzepatide linked to more GI issues than semaglutide in new study on weight-loss drugs without diabetes. Read more!

If you're starting a semaglutide GLP-1 RA medication like Wegovy or Ozempic for weight loss, you may be wondering how soon ...